IVA

Healthcare Biotechnology

Inventiva S.A.

$3.48

-0.10 -2.69% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 5, 2026, live at 3:05 PM ET	3.48

Key Stats

Market Cap

822.05M

Avg Volume

1.44M

EPS

-$0.62

52W High

$7.98

52W Low

$3.11

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-4.63

P/B Ratio

12.36

P/S Ratio

334.71

EV/EBITDA

-5.46

EV/Revenue

331.36

Margins

Gross Margin 78.3%

Operating Margin (5337.3%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

(76.7%)

Return on Equity

(989.1%)

Return on Assets

(42.7%)

Liquidity & Leverage

Current Ratio

3.81

Quick Ratio

2.73

Debt / Equity

2.35

Total Cash

166.13M

Total Debt

138.79M

About

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

inventivapharma.com